Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.

At 3:08 p.m. ET (20:08 GMT), the Dow Jones Industrial Average traded 120 points, or 0.3%, the S&P 500 index fell 0.01% after ...

A barrage of weak economic data and the announcement of a whole new set of US import tariffs weighed heavily on Wall Street on Friday, with stocks finishing the week with heavy losses.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its ...